Welcome to LookChem.com Sign In|Join Free
  • or
4-[(2,4-difluorobenzyl)oxy]-3-methoxybenzaldehyde is a chemical with a specific purpose. Lookchem provides you with multiple data and supplier information of this chemical.

883975-24-4

Post Buying Request

883975-24-4 Suppliers

Recommended suppliers

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

883975-24-4 Usage

Check Digit Verification of cas no

The CAS Registry Mumber 883975-24-4 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 8,8,3,9,7 and 5 respectively; the second part has 2 digits, 2 and 4 respectively.
Calculate Digit Verification of CAS Registry Number 883975-24:
(8*8)+(7*8)+(6*3)+(5*9)+(4*7)+(3*5)+(2*2)+(1*4)=234
234 % 10 = 4
So 883975-24-4 is a valid CAS Registry Number.

883975-24-4Relevant academic research and scientific papers

Quinazoline derivatives as selective CYP1B1 inhibitors

Mohd Siddique, Mohd Usman,McCann, Glen J.P.,Sonawane, Vinay R.,Horley, Neill,Gatchie, Linda,Joshi, Prashant,Bharate, Sandip B.,Jayaprakash, Venkatesan,Sinha, Barij N.,Chaudhuri, Bhabatosh

, p. 320 - 327 (2017)

CYP1B1 is implicated to have a role in the development of breast, ovarian, renal, skin and lung carcinomas. It has been suggested that identification of potent and specific CYP1B1 inhibitors can lead to a novel treatment of cancer. Flavonoids have a compact rigid skeleton which fit precisely within the binding cavity of CYP1B1. Systematic isosteric replacement of flavonoid ‘O’ atom with ‘N’ atom led to the prediction that a ‘quinazoline’ scaffold could be the basis for designing potential CYP1B1 inhibitors. A total of 20 quinazoline analogs were synthesized and screened for CYP1B1 and CYP1A1 inhibition in Sacchrosomes. IC50 determinations of six compounds with capability of inhibiting CYP1B1 identified quinazolines 5c and 5h as the best candidates for CYP1B1 inhibition, with IC50 values in the nM range. Further selectivity studies with homologous CYPs, belonging to the CYP1, CYP2 and CYP3 family of enzymes, showed that the compounds are likely to be free from critical drug-drug interaction liability. Molecular modelling studies were performed to rationalize the observed enzymatic inhibitions. Further biological studies in live yeast and human cells, harboring CYP1A1 and CYP1B1 enzymes, have illustrated the most potent compounds' cellular permeability and capability of potently inhibiting CYP1B1 enzyme expressed within live cells.

SUBSTITUDED BENZYLOXY-PHENYLMETHYLUREA DERIVATIVES

-

Page/Page column 23, (2010/11/28)

The present invention relates to novel substituted benzyloxy-phenylmethylurea derivatives, processes for their preparation, and their use in medicaments, especially for the prophylaxis and treatment of diseases associated with Cold Menthol Receptor 1 (CMR

SUBSTITUTED 4-BENZYLOXY-PHENYLMETHYLAMIDE DERIVATIVES AS COLD MENTHOL RECEPTOR-1 (CMR-1) ANTAGONISTS FOR THE TREATMENT OF UROLOGICAL DISORDER

-

Page/Page column 21, (2008/06/13)

The present invention relates to novel substituted benzyloxy-phenylmethylamide derivatives of formula (I), processes for their preparation, and their use in medicaments, especially for the prophylaxis and treatment of diseases associated with Cold Menthol

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1 Customer Service

What can I do for you?
Get Best Price

Get Best Price for 883975-24-4